Home / Rare & Genetic Diseases
Rare & Genetic Diseases
| 2 min read
BioServe will use its Global Repository—which comprises more than 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic information—to assist the Specialized Clinical Center of Research (SCCOR) conduct a novel study aimed at identifying the genetic cause of thoracic aortic disease. The repository was the key asset of Genomics Collaborative which was recently acquired by BioServe (DDN, June 2007).
| 1 min read
Attendees of the recent Rachmiel Levine Diabetes and Obesity Symposium
| 3 min read
Most people have a soft spot for orphans. These unfortunate souls, often depicted with unusually large and needy eyes, tug at the heartstrings.
Such has not always been the case in the pharmaceutical industry, where an orphan is a treatment for a rare disease that occurs in fewer than 200,000 people in the United States, as defined by the FDA’s Orphan Drug Act, passed in 1983.
| 3 min read
I must admit to wondering sometimes why anyone in his or her right mind would even consider a career in the pharmaceutical industry.
| 3 min read
Pharma is unlike any other industry; pass it on
Imust admit to wondering sometimes why anyone in his or her right mind would even consider a career in the pharmaceutical industry.
| 2 min read
In a deal between Adherex and GlaxoSmithKline (GSK) penned in July, Adherex received an exclusive license to the oncology product eniluracil for all indications, while GSK gained an option to license Adherex’s lead biotechnology compound, ADH-1.
